These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25790771)

  • 1. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.
    He X; Chen P; Yang K; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
    Acta Haematol; 2015; 133(4):365-371. PubMed ID: 25790771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.
    Zhuo W; Zhang L; Ling J; Zhu B; Chen Z
    Leuk Lymphoma; 2012 Nov; 53(11):2245-52. PubMed ID: 22563815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.
    Ou WB
    Med Sci Monit; 2015 Jan; 21():213-8. PubMed ID: 25600314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
    Yan YL; Han F; Tan WM; Wu CP; Qin X
    Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis.
    Kong Q; Li P; Tian Q; Ha MW
    Genet Test Mol Biomarkers; 2014 May; 18(5):357-65. PubMed ID: 24673452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
    Yin L; Shen G; Zhu B
    Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
    Xue Z; Zhu X; Teng Y
    Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
    Economopoulos KP; Sergentanis TN
    Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between murine double minute 2 T309G polymorphism and risk of liver cancer.
    Tang T; Song X; Yang Z; Huang L; Wang W; Tan H
    Tumour Biol; 2014 Nov; 35(11):11353-7. PubMed ID: 25119589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.
    Zhuo W; Zhang L; Zhu B; Ling J; Chen Z
    PLoS One; 2012; 7(7):e41546. PubMed ID: 22844496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
    Ma HB; Huang T; Han F; Chen WY
    Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
    Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
    Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between MDM2 T309G Polymorphism and Leukemia in the Chinese Population: Evidence from a Meta-Analysis.
    Zhao D; Liu T
    Clin Lab; 2017 Oct; 63(10):1639-1645. PubMed ID: 29035454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
    Tang J; Shen L; Song S; An Z; Zhang C
    Tumour Biol; 2014 Jan; 35(1):779-84. PubMed ID: 23979978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals.
    Zhuo X; Ye H; Li Q; Xiang Z; Zhang X
    Medicine (Baltimore); 2016 Mar; 95(9):e2948. PubMed ID: 26945408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.